Key Takeaways

• The FDA-approved commercial GLP-1 pathway (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda) is the compliant baseline. Practices operating on branded product with commercial payor billing sit in the safest regulatory posture.
• The compounded GLP-1 pathway has narrowed materially. The 503A patient-specific compounding exception remains available for documented individualized medical necessity, but the shortage-list pathway that supported broad 503A and 503B compounding through 2024 has closed. Compounding without documented medical necessity, unlicensed manufacturing, poor API sourcing, and marketing that exceeds evidence are all current FDA enforcement priorities.
• California CPOM applies fully. GLP-1 prescribing is the practice of medicine, and the clinical entity has to be a physician-owned professional corporation under Cal. Corp. Code § 13401.5. LLCs cannot render medical services under § 17701.04(e).
• Buyer diligence on a GLP-1 target has to distinguish between (a) branded-product practices, (b) practices that compounded lawfully during the shortage window and have transitioned to compliant supply, and (c) practices whose compounding operation depends on the enforcement gaps regulators have been narrowing. The three categories have very different risk profiles.
• Two related exposure categories run alongside CPOM: FDA warning-letter risk for marketing that overstates outcomes or safety, and payor recoupment for coverage claims that don’t hold up post-audit.

Buying a GLP-1 or Medical Weight-Loss Clinic in California: A Non-Licensee Buyer’s Guide

The GLP-1 landscape changed materially between 2024 and 2026, and a target that was compliant to acquire two years ago may not be compliant to acquire now. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025. Enforcement discretion for compounders ended in phases through mid-2025. In February 2026, the FDA publicly announced enforcement intent against non-FDA-approved GLP-1 drugs. On March 3, 2026, the FDA issued warning letters that prompted Hims & Hers to substantially withdraw from compounded GLP-1 marketing. On April 30, 2026, the FDA published a proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, with a public comment period through June 29, 2026.

None of this makes GLP-1 practice unlawful. It makes buyer diligence on compounding-dependent GLP-1 practices considerably more careful than it was 18 months ago. This post walks through the current framework and the acquisition-specific issues. It sits under the buyer pillar for the CPOM Acquisition & Remediation cluster and is the companion to the ketamine and HRT modality-specific buy posts.

The Regulatory Timeline Every GLP-1 Buyer Needs to Understand

The buyer’s diligence framework depends on when the target’s compounding practices developed and whether the practice has adjusted to the current framework. A brief chronology, framed as of drafting:

• 2022–2024. GLP-1 shortages on the FDA drug shortage list opened 503A patient-specific compounding and 503B outsourcing-facility compounding at scale. Compounded semaglutide and tirzepatide reached patients at $150–$300 per month against $1,000+ branded pricing. Widespread practice growth in medical weight-loss, med spa, and telehealth-forward compounded GLP-1 delivery.
• Late 2024 to early 2025. FDA declared tirzepatide shortage resolved December 2024 and semaglutide shortage resolved February 2025. Enforcement discretion for 503A pharmacies ended April 22, 2025 (semaglutide) and roughly the same window for tirzepatide. 503B enforcement discretion extended briefly (through May 22, 2025 for semaglutide; March 19, 2025 for tirzepatide).
• 2025 mid-year through early 2026. Outsourcing Facilities Association sued FDA on the shortage-list determinations. Preliminary injunctions denied. Enforcement deadlines held.
• February 2026. FDA publicly announced enforcement intent against non-FDA-approved GLP-1 drugs. Enforcement priorities clarified: compounding without documented medical necessity; unlicensed manufacturing; misleading marketing; improper storage and shipping; poor API sourcing; research-grade ingredients not intended for human use.
• March 3, 2026. FDA warning letters. Novo Nordisk announced partnership with Hims & Hers; Hims & Hers substantially withdrew from compounded GLP-1 marketing.
• April 30, 2026. FDA published proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Public comment period through June 29, 2026.

The practical implication for a buyer: a GLP-1 target’s compounding practices in 2023 may have been fully compliant with the framework at the time, and the same practices in 2026 may not be. The buyer’s diligence has to identify what the target does now, not what the target did then — and to assess whether the current practice has adjusted appropriately.

The Three Compliance Postures a Buyer Sees

Posture 1: Branded product only. The target prescribes Ozempic, Wegovy, Mounjaro, Zepbound, or Saxenda; the pharmacy dispenses the FDA-approved commercial product; patients pay cash or use commercial insurance. This is the safest posture. Diligence emphasis: CPOM structure, the good-faith exam workflow (this matters — buyer’s counsel should check whether the practice is doing genuine clinical evaluation before prescribing, since the FDA has emphasized medical necessity), payor billing accuracy (Wegovy and Zepbound coverage requires specific BMI and comorbidity criteria), and the general CPOM diligence framework.

Posture 2: Post-transition compounded practice. The target compounded semaglutide or tirzepatide during the shortage window (2022–early 2025), then transitioned to a compliant post-shortage practice. The transition might mean shifting patients to branded product; shifting compounding to genuinely patient-specific 503A formulations with documented medical necessity for compounded (rather than commercially available) forms; or exiting compounded product entirely. Diligence emphasis: what the transition actually looked like; historical exposure for the pre-transition compounding period (largely resolved if the compounding was compliant at the time, but worth confirming); current 503A relationships and medical-necessity documentation; and payor and marketing exposure from the transition period.

Posture 3: Compounded practice operating in the current enforcement gap. The target continues to prescribe compounded semaglutide, tirzepatide, or liraglutide at scale, sourcing from 503A pharmacies or (more concerning) unregistered sources. Medical necessity documentation is often thin or absent. Marketing may still position compounded product as equivalent to or better than branded product. This is where the FDA’s 2026 enforcement priorities are focused, and this is where a buyer inherits the most exposure. Diligence has to be candid about what the practice is actually doing and whether the buyer wants to continue those operations post-closing.

The three postures are on a continuum, and many targets sit somewhere in the middle. The buyer’s job is to identify where the specific target sits and to price the deal (or walk) accordingly.

GLP-1 Compounding Diligence — the Detailed Questions

Where the target relies on compounded GLP-1, buyer diligence should surface:

Which specific product is being compounded and from what source. Semaglutide, tirzepatide, and liraglutide are the three products the FDA’s April 30, 2026 proposed rule targets. Dulaglutide and (per some sources) liraglutide may still appear on the FDA drug shortage list in 2026, which affects the analysis for those specific products.

The compounding pharmacy’s registration status. 503A pharmacies are state-licensed and compound for individual patients based on individual prescriptions. 503B outsourcing facilities register with the FDA and can compound in bulk under specific conditions. Both are legal categories when properly used; both have narrower current scopes than in 2022–2024.

Medical necessity documentation. The 503A pathway requires patient-specific compounding based on an individual prescription for a patient with a specific medical need. Medical necessity that survives scrutiny typically involves clinical circumstances the commercial product cannot address — allergies to inactive ingredients, dosing regimens not commercially available, or supply issues for the specific patient. “Cheaper than the branded product” is not medical necessity.

Whether the compounded product is “essentially a copy” of the commercial drug. Under the FD&C Act, 503A compounding cannot produce a drug that is “essentially a copy” of a commercially available FDA-approved drug. Post-shortage semaglutide compounded at the same dose, route, and delivery as commercial Ozempic or Wegovy raises this concern.

API sourcing. Bulk drug substance for compounding has to be sourced from FDA-registered facilities, meeting specified purity and quality standards. Research-grade API not intended for human use is an FDA enforcement priority and a diligence red flag.

Marketing representations. Does the target’s marketing represent compounded product as equivalent to, safer than, or more effective than branded product? Does it minimize the FDA’s public safety concerns about compounded GLP-1? Does it use “medically supervised” or “physician-supervised” language that overstates the practice’s actual clinical structure?

CPOM Diligence for GLP-1 Practices

The general treatment-business CPOM framework applies. Four issues warrant particular attention for GLP-1 practices:

Entity structure. The clinical entity has to be a physician-owned professional corporation. LLCs and non-physician corporations cannot render medical services. Weight-loss “programs” branded as coaching or wellness that in practice include prescribing GLP-1 medications are subject to the same CPOM framework — the marketing label doesn’t change the underlying practice of medicine.

Good-faith exam and medical necessity. The GFE for GLP-1 prescribing has to establish medical necessity (typically documented hypogonadism, diabetes, obesity meeting BMI thresholds, or comorbidity indications). The 2026 California GFE standard treats standing orders as insufficient — patient-specific orders based on a good-faith exam by a licensed prescriber (physician, NP, or PA) under B&P § 2242 are the operational baseline. Practices that have been running on questionnaire-only asynchronous intake with rubber-stamp prescriber approval are operating below the current standard.

Nurse practitioner and physician assistant participation. AB 890 104 NPs may prescribe GLP-1 medications within their full-practice authority. Traditional NPs and PAs operating under standardized procedures or supervision agreements may prescribe within the delegation framework. Diligence should confirm each prescribing clinician’s authority category and, for controlled-substance-adjacent prescribing, DEA registration where applicable.

Marketing and results claims. GLP-1 marketing that promises specific weight-loss outcomes (“lose 20 pounds in 3 months”), that overstates typical results, that fails to disclose adverse-event risks (nausea, vomiting, pancreatitis risk signals, gastroparesis reports, potential thyroid concerns from animal studies), or that uses influencer content without appropriate disclosures is a false-advertising exposure category under B&P § 17500 alongside the underlying CPOM analysis.

Payor Considerations for GLP-1 Practices

Commercial payor coverage for GLP-1 medications is limited. Wegovy and Zepbound are FDA-approved for chronic weight management with specific BMI and comorbidity criteria. Coverage varies by plan and by employer group. Ozempic and Mounjaro are approved for type 2 diabetes; off-label prescribing for weight loss without diabetes diagnosis raises coverage and audit issues.

Buyer diligence.

• Payor participation list; billing volume by CPT code for the last twelve months.
• Denial rates and audit history — GLP-1 coverage audits have increased with the pricing pressure.
• Coding practices — using diabetes diagnosis codes for patients without documented diabetes is a payor recoupment risk and a False Claims Act risk for practices that participate in federal payor programs.
• Superbill practices — practices offering superbill support to patients seeking commercial insurance reimbursement carry their own compliance layer around what the superbill represents.

When to Bring Counsel Into a GLP-1 Acquisition

Before the LOI is signed. GLP-1 is one of the categories where the regulatory framework has moved fastest in recent memory, and a target’s compliance posture reflects the framework at the time the practice was built. Pre-LOI structural counsel is where the deal is either built for the current framework or set up to inherit the seller’s exposure to a framework that has changed.

Bay Legal, PC represents non-licensee buyers of California GLP-1 and medical weight-loss practices through pre-LOI structural counsel, FDA and CPOM diligence, and deal documentation. Call (650) 668-8000 or schedule a consultation at baylegal.com/contact.

Frequently Asked Questions

Is it still legal to buy a compounded-GLP-1-focused practice in California?

Legal to acquire, yes. Whether the target’s specific compounding operation is currently compliant is the diligence question. 503A patient-specific compounding remains available for documented individualized medical necessity. Compounding that produces a drug “essentially a copy” of Ozempic or Wegovy is not the intended use of the 503A pathway. The FDA’s 2026 enforcement priorities are focused on the operations that stretch the 503A framework beyond its intended scope. Buyer diligence has to identify what the target actually does and how the practice has adjusted (or not) to the post-shortage framework.

What changed on April 30, 2026?

The FDA published a proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the list of bulk drug substances that outsourcing facilities may use in compounding under § 503B. If finalized, the rule would close one of the remaining pathways for 503B compounding of these drugs. The public comment period ran through June 29, 2026; the final rule has not issued as of drafting. Confirm current status at federalregister.gov before finalizing deal timing.

Can a non-physician own a GLP-1 clinic?

Not the clinical entity. Cal. Corp. Code § 13401.5 reserves ownership of California medical corporations to licensed physicians (with up to 49% allied-professional minority shareholders in specific categories). Non-physicians can own MSOs that contract with physician-owned PCs providing GLP-1 clinical services. This is the standard friendly-PC + MSO structure that applies across California treatment businesses.

Does the practice need to use synchronous video for the good-faith exam?

For most GLP-1 patients, live evaluation — in person or by synchronous video, is treated as the current standard by California’s Medical Board and BRN, particularly given the risk profile of GLP-1 medications (BMI screening, comorbidity evaluation, contraindication review, adverse-event risk counseling). Well-designed questionnaires reviewed by a qualified prescriber can support GFE for lower-risk medication management, but the 2026 posture has moved toward more robust evaluation for medications with meaningful risk profiles, and GLP-1 medications sit in that category.

What is the biggest single diligence question for a GLP-1 acquisition in 2026?

Whether the target’s compounded product operations have adjusted to the post-shortage framework. A target that continues to prescribe compounded semaglutide or tirzepatide at scale, with thin medical-necessity documentation, and with marketing that positions compounded product as equivalent to branded, is a target sitting in the exact center of the FDA’s 2026 enforcement focus. A target that has transitioned to branded product, or that maintains only genuinely patient-specific 503A compounding with documented medical necessity, is a very different acquisition. The compounding-transition question is often one of the central diligence lines.

Talk to a California GLP-1 Acquisition Attorney

Bay Legal, PC represents non-licensee buyers of California GLP-1 and medical weight-loss practices. Whether the target operates on branded product, compounded product, or a hybrid, we can help you structure the deal for the current framework. Call (650) 668-8000 or schedule a consultation at baylegal.com/contact.